0001104659-17-002824.txt : 20170118 0001104659-17-002824.hdr.sgml : 20170118 20170118170200 ACCESSION NUMBER: 0001104659-17-002824 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170113 FILED AS OF DATE: 20170118 DATE AS OF CHANGE: 20170118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC CENTRAL INDEX KEY: 0001621227 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 101 PARK DRIVE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RY BUSINESS PHONE: 44 1235 430000 MAIL ADDRESS: STREET 1: 101 PARK DRIVE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RY FORMER COMPANY: FORMER CONFORMED NAME: Adaptimmune Ltd DATE OF NAME CHANGE: 20141001 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rawcliffe Adrian CENTRAL INDEX KEY: 0001555851 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37368 FILM NUMBER: 17534010 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD STATE: X0 ZIP: TW9 9GS 4 1 a4.xml 4 X0306 4 2017-01-13 0 0001621227 Adaptimmune Therapeutics PLC ADAP 0001555851 Rawcliffe Adrian 440 SOUTH BROAD STREET, UNIT 1803 PHILADELPHIA PA 19146 0 1 0 0 Chief Financial Officer Option to purchase Ordinary Shares 0.72 2017-01-13 4 A 0 2072976 0 A 2027-01-13 Ordinary Shares 2072976 2072976 D The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021. /s/ Adrian Rawcliffe 2017-01-18